About TauRx
TauRx is a Healthcare company based in Singapore (Singapore) founded in 2002 by K M Seng, Claude Wischik, and Chung Meng Goh. Treatments for Alzheimers and neurodegenerative diseases are developed. TauRx has raised $433.84 million across 6 funding rounds from investors including Genting Singapore, Charite and University of Aberdeen. The company has 76 employees. TauRx was last valued at $2.5 billion in March 2018. Its chief executive, as recorded, is Claude Wischik. TauRx offers products and services including HMTM. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its legal entity is TauRx Pharmaceuticals Ltd.
Company details
TauRx was founded in 2002 in Singapore and operates in the biotechnology sector. Focus is placed on developing and commercializing therapies that target tau pathology in neurodegenerative diseases, including Alzheimers disease and frontotemporal dementia. Research and development activities encompass clinical trials and partnerships to progress therapeutic candidates. A key drug in the pipeline is currently undergoing regulatory review for mild cognitive impairment and mild to moderate Alzheimers disease.
- Annual Revenue$783.65 K (USD)-34as on Jul 01, 2023
- Net Profit-$16.16 M (USD)-10as on Jul 01, 2023
- EBITDA-$16.09 M (USD)-7as on Jul 01, 2023
- Total Equity Funding$433.84M (USD)
in 6 rounds
- Latest Funding Round$119M (USD), Series E
Nov 2022
- InvestorsGenting Singapore
& 11 more
- Employee Count76
Products & Services of TauRx
TauRx offers a comprehensive portfolio of products and services, including HMTM.
Inhibits tau aggregation to treat Alzheimer's and cognitive impairment.
Funding Insights of TauRx
TauRx has successfully raised a total of $433.84M across 6 strategic funding rounds. The most recent funding activity was a Series E round of $119 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $433.84M
- Total Rounds 6
- Last Round Series E — $119M
- First Round $20M
(Sep 2011)
- Investors Count 12
All 6 funding rounds of TauRx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2022 | $119M | Series E | – | – | – |
| Jul 2016 | $117.84M | Series D | – | – | – |
| Oct 2015 | $135M | Series D | – | – | – |
| Mar 2013 | $10.5M | Series B | – | Dundee Corporation | – |
| Nov 2012 | $31.5M | Series B | – | Genting Singapore | – |
| Sep 2011 | $20M | Series A | – | Dundee Corporation | – |
| Date | Valuation | Stage |
|---|
Full valuation and stage history of TauRx
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $2.5B (Mar 2018). 12 investors in total: 10 institutional and 2 angel.
Investors in TauRx
TauRx has secured backing from 12 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Genting Singapore, Charite and University of Aberdeen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| venstar-capital.com | ||||
Diversified holding company engaged in wealth management, resources, agriculture and real estate areas | 1984 | dundeecorporation.com | Toronto, Canada | |
Provider of resort development services | 1984 | gentingsingapore.com | Singapore, Singapore | |
FIDES Capital Partners is engaged in real estate advisory and investment. | fidescp.com | |||
LNS is engaged in tunneling, mining, and infrastructure construction. | lns.no | Risøyhamn, Norway | ||
Information and education services for healthcare industries are provided. | 1710 | charite.de | Berlin, Germany | |
Brokerage services and investment products are provided to investors worldwide. | 1970 | uobkayhian.com | Singapore, Singapore | |
Multiple courses and degrees are offered across diversified academic streams. | 1495 | abdn.ac.uk | Aberdeen, United Kingdom | |
| easternepic.vc |
Investor details for TauRx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of TauRx
19 people are tracked at TauRx (8 in leadership, 9 in board & advisors, 2 in team); the tracked headcount is 76.
| Name | Role | Group |
|---|---|---|
K M Seng | Co-Founder | Leadership |
Claude Wischik | Co-Founder & CEO | Leadership |
Chung Meng Goh | Co-Founder & COO | Leadership |
Glenn Corr | COO | Leadership |
Hwang Hong Wei | Finance Director | Leadership |
Richard G. Stefanacci | Chief Medical Officer | Leadership |
John Storey | Head Of Technical | Leadership |
Charles Harrington | Chief Scientific Officer | Leadership |
Tan Sri Lim Kok Thay | Director | Board & advisors |
Stephen Logan | Director | Board & advisors |
Tan Kong Han | Director | Board & advisors |
Paul Cheng | Director | Board & advisors |
Tay Siew Choon | Deputy Chairman | Board & advisors |
Seng Shay Way | Director | Board & advisors |
George Chia | Director | Board & advisors |
Celine Tang | Director | Board & advisors |
Sushilan Vasoo | Director | Board & advisors |
Lawrence Wong Kin Meng | Company Secretary & Legal Advisor | Team |
Shirley Liu | Senior Finance Manager | Team |
Complete people profiles for TauRx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of TauRx
4 dated milestones of TauRx across 20 years, from founding to its latest funding, stage changes and deals.
- Founded TauRx is founded.
- Funding First funding round of $20.0M.
- Milestone Reaches Unicorn status.
- Funding Latest funding round, Series E, of $119.0M.
Web traffic of TauRx
The website of TauRx (taurx.com) receives about 8.1K visits a month and ranks #2,623,902 among all websites worldwide, #3,588 in Biotechnology and Pharmaceuticals.
- Monthly visits8.1K
▼ 5.4% vs previous month
- Unique visitors3.2K
per month
- Global rank#2,623,902
among all websites
- Category rank#3,588
Health · Biotechnology and Pharmaceuticals
- Bounce rate49%
- Pages per visit1.6
- Average visit14 sec
- DevicesDesktop 40% · Mobile 60%
Websites whose visitors overlap most with TauRx. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| addextherapeutics.com | 100% | 3.3K | #7,605,013 | View details | |
idpl.gov.in | idpl.gov.in | 62% | – | ||
alzforum.org | alzforum.org | 56% | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Taurx
Complete news archive for TauRx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TauRx
TauRx was founded in 2002 and raised its 1st funding round 9 years after it was founded.
TauRx is headquartered in Singapore, Singapore. It is registered at Singapore, Singapore, Singapore.
Claude Wischik is the CEO of TauRx, as recorded in our data. They have also founded this company.
TauRx is a funded company, having raised a total of $433.84M across 6 funding rounds to date. The company's 1st funding round was a Series A of $20M, raised on Sep 2011.
TauRx has 76 employees.
Annual revenue of TauRx is $783.65K as on Jul 01, 2023.
TauRx was founded in 2002 in Singapore and operates in the biotechnology sector. Focus is placed on developing and commercializing therapies that target tau pathology in neurodegenerative diseases, including Alzheimers disease and frontotemporal dementia. Research and development activities encompass clinical trials and partnerships to progress therapeutic candidates. A key drug in the pipeline is currently undergoing regulatory review for mild cognitive impairment and mild to moderate Alzheimers disease.
TauRx has 12 investors. Key investors include Genting Singapore, Charite, University of Aberdeen, UOB Kay Hian, and Dundee Corporation.
The valuation of TauRx is $2.5B as of Mar 2018.
TauRx operates through Taurx Pharmaceuticals Ltd..